The White House’s Drug Pricing “Blueprint”

Last Friday, the White House released a Blueprint outlining proposals for reducing prescription drug costs. Some of these proposals may be implemented through the issuance of regulations or other authorized agency action, while other proposals may first require congressional authorization via the enactment of new legislation.

The Blueprint’s proposals highlight the Trump administration’s belief that drug prices should be reduced by promoting competition and altering misaligned incentives. Although the Trump administration has made strong statements about high drug prices, the Blueprint’s proposals — if implemented — would not appear to impose onerous burdens on the pharmaceutical industry.